Host: The Japanese Society of Toxicology
Name : The 47th Annual Meeting of the Japanese Society of Toxicology
Date : 2020 -
Immune checkpoint inhibitors, bispecific T-cell engagers and CAR-T therapy have provided unique therapeutic effects. Currently, great efforts are underway to develop various therapeutics of these platforms. These therapeutics have excellent therapeutic effects and severe adverse effects. The most frequent and common adverse effect is cytokine release syndrome (CRS) that often becomes dose-limiting toxicity. Recent mechanistic investigations have suggested possibility of prevention of severe CRS without reducing anti-tumor activities. Here, I would like to review the findings of the recent CRS investigations suggesting potential measures to control severe CRS.
